USANA Health Sciences (NYSE:USNA) Earns Hold Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of USANA Health Sciences (NYSE:USNA) in a research note released on Thursday, 24/7 WallStreet reports. The firm issued a hold rating and a $65.00 price target on the stock.

Several other brokerages also recently weighed in on USNA. Pivotal Research reiterated a buy rating on shares of USANA Health Sciences in a report on Wednesday, July 24th. TheStreet downgraded USANA Health Sciences from a b- rating to a c+ rating in a report on Thursday, July 11th. ValuEngine upgraded USANA Health Sciences from a sell rating to a hold rating in a report on Thursday, August 1st. Finally, Sidoti cut shares of USANA Health Sciences from a buy rating to a neutral rating and set a $70.00 price objective for the company. in a research note on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $70.00.

Shares of USNA opened at $64.29 on Thursday. The stock has a fifty day moving average of $64.96 and a two-hundred day moving average of $80.58. The company has a market capitalization of $1.50 billion, a PE ratio of 12.46 and a beta of 0.44. USANA Health Sciences has a fifty-two week low of $58.30 and a fifty-two week high of $134.65.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported $0.91 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.93 by ($0.02). The business had revenue of $256.00 million during the quarter, compared to analyst estimates of $254.66 million. USANA Health Sciences had a net margin of 9.68% and a return on equity of 27.22%. The company’s revenue was down 15.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.36 earnings per share. As a group, research analysts anticipate that USANA Health Sciences will post 3.9 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new stake in shares of USANA Health Sciences during the 2nd quarter valued at $27,000. Royce & Associates LP grew its stake in shares of USANA Health Sciences by 66.4% during the 1st quarter. Royce & Associates LP now owns 381 shares of the company’s stock valued at $32,000 after buying an additional 152 shares during the period. LS Investment Advisors LLC purchased a new stake in shares of USANA Health Sciences during the 2nd quarter valued at $32,000. Advisory Services Network LLC purchased a new stake in shares of USANA Health Sciences during the 2nd quarter valued at $65,000. Finally, NEXT Financial Group Inc purchased a new stake in shares of USANA Health Sciences during the 2nd quarter valued at $79,000. 66.39% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: What is the Coverage Ratio?

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.